According to these assumptions, statins [30] and ACE inhibitors (ACE-I) [31], because of their effect on reducing endothelial dysfunction, might find a rationale in the management of COVID-19 patients, as well as the reduction of low density lipoprotein (which reduces eNOS activity) [32] and the increased consumption of resveratrol (which induces eNOS activity and expression) [33]. Here, ACE is linked to COVID-19.